Austrian biotech Marinomed is weighing up strategic options for its virus-blocking compound Carragelose, out-licensed to major consumer health players such as Perrigo, Reckitt and Procter & Gamble for use in OTC nasal sprays.
Marinomed Exploring Options For Virus-Blocking OTC Nasal Spray Platform
The virus-blocking platform used in OTC nasal sprays marketed by Perrigo and Reckitt, amongst others, developed by Austria's Marinomed is up for sale.
More from Strategy
• By
Round up of the latest appointments: PAGB names vice presidents; Activ'Inside gets first US head; EMA elects management board chair.
• By
A round-up of the latest consumer health industry appointments: GSCF elects chair; Kenvue hires Northern Europe head; Barentz names chief commercial officer.
• By
Galenica outpaced the growth of the OTC market at home, while recording a double-digit gain abroad, to drive up its consumer health product sales in 2024.
• By
Alliance shareholders overwhelmingly back takeover by DBAY Advisors after improved offer values UK-based firm at £362m.
More from Business
• By
Alliance shareholders overwhelmingly back takeover by DBAY Advisors after improved offer values UK-based firm at £362m.
• By
Like many European firms, Stada Arzneimittel's 2024 earnings were held back by a soft cough, cold and flu season. However, key launches in its home market Germany and in the Middle East offset this impact and led to 3% organic growth for Stada's Consumer Healthcare business.
• By
Key growth driver in consumer health and across Bayer’s sectors, says CEO Bill Anderson, is “dynamic shared ownership program” introduced in January 2024 to "reduce hierarchies, eliminate bureaucracy, streamline structures and accelerate decision-making processes."